Business Context and Reporting Period
Company: Cara Therapeutics, Inc. (Note: Request metadata listed "Tvardi Therapeutics, Inc.", but the filing identifies the registrant as Cara Therapeutics, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: March 9, 2017
Reporting Period: Fourth quarter and full year ended December 31, 2016.
Key Financial Metrics
This Form 8-K serves as a notification of a press release regarding financial results. The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained in the press release furnished as Exhibit 99.1, which is incorporated by reference but not reproduced in this document.
Material Changes
The filing announces the release of financial results for the fourth quarter and year ended December 31, 2016. No specific material changes or comparative data are detailed within the text of this 8-K.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on March 9, 2017, detailing its financial results.
Forward-Looking Statements: The filing explicitly states that the information furnished pursuant to Item 2.02 shall not be deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section. The Company undertakes no duty or obligation to publicly update or revise the information furnished, except as required by law.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing the press release attached as Exhibit 99.1.
- Confirm the company name is Cara Therapeutics, Inc., as the metadata provided in the request contained a discrepancy.
- Note that the 8-K text does not contain the actual financial data, only the announcement of its release.
- Review the press release for any updated guidance or operational milestones for 2017.